Gene- and pathway-level analyses of iCOGS variants highlight novel signaling pathways underlying familial breast cancer susceptibility.


Journal

International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124

Informations de publication

Date de publication:
15 04 2021
Historique:
received: 17 09 2020
revised: 20 11 2020
accepted: 07 12 2020
pubmed: 29 12 2020
medline: 3 8 2021
entrez: 28 12 2020
Statut: ppublish

Résumé

Single-nucleotide polymorphisms (SNPs) in over 180 loci have been associated with breast cancer (BC) through genome-wide association studies involving mostly unselected population-based case-control series. Some of them modify BC risk of women carrying a BRCA1 or BRCA2 (BRCA1/2) mutation and may also explain BC risk variability in BC-prone families with no BRCA1/2 mutation. Here, we assessed the contribution of SNPs of the iCOGS array in GENESIS consisting of BC cases with no BRCA1/2 mutation and a sister with BC, and population controls. Genotyping data were available for 1281 index cases, 731 sisters with BC, 457 unaffected sisters and 1272 controls. In addition to the standard SNP-level analysis using index cases and controls, we performed pedigree-based association tests to capture transmission information in the sibships. We also performed gene- and pathway-level analyses to maximize the power to detect associations with lower-frequency SNPs or those with modest effect sizes. While SNP-level analyses identified 18 loci, gene-level analyses identified 112 genes. Furthermore, 31 Kyoto Encyclopedia of Genes and Genomes and 7 Atlas of Cancer Signaling Network pathways were highlighted (false discovery rate of 5%). Using results from the "index case-control" analysis, we built pathway-derived polygenic risk scores (PRS) and assessed their performance in the population-based CECILE study and in a data set composed of GENESIS-affected sisters and CECILE controls. Although these PRS had poor predictive value in the general population, they performed better than a PRS built using our SNP-level findings, and we found that the joint effect of family history and PRS needs to be considered in risk prediction models.

Identifiants

pubmed: 33368296
doi: 10.1002/ijc.33457
pmc: PMC9290690
doi:

Substances chimiques

BRCA1 Protein 0
BRCA1 protein, human 0
BRCA2 Protein 0
BRCA2 protein, human 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1895-1909

Informations de copyright

© 2020 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.

Références

Int J Cancer. 2021 Apr 15;148(8):1895-1909
pubmed: 33368296
Nat Genet. 2017 Dec;49(12):1767-1778
pubmed: 29058716
Nat Genet. 2013 Apr;45(4):353-61, 361e1-2
pubmed: 23535729
Nat Genet. 2006 Aug;38(8):873-5
pubmed: 16832357
Nature. 2005 Apr 14;434(7035):917-21
pubmed: 15829967
Nat Genet. 2013 Apr;45(4):385-91, 391e1-2
pubmed: 23535732
J Invest Dermatol. 2016 Mar;136(3):593-602
pubmed: 26743605
Int J Cancer. 2013 Feb 15;132(4):924-31
pubmed: 22689255
BMC Cancer. 2016 Jan 12;16:13
pubmed: 26758370
Int J Cancer. 2019 Apr 15;144(8):1962-1974
pubmed: 30303537
Nat Rev Genet. 2010 Dec;11(12):843-54
pubmed: 21085203
Breast Cancer Res. 2013 Feb 28;15(1):R17
pubmed: 23448497
Nucleic Acids Res. 2010 Jul;38(Web Server issue):W90-5
pubmed: 20435672
Nucleic Acids Res. 2018 Jan 4;46(D1):D971-D976
pubmed: 29036324
Eur J Hum Genet. 2011 Jul;19(7):807-12
pubmed: 21407268
Am J Hum Genet. 2019 Jan 3;104(1):21-34
pubmed: 30554720
Twin Res Hum Genet. 2015 Feb;18(1):86-91
pubmed: 25518859
N Engl J Med. 2014 Aug 7;371(6):497-506
pubmed: 25099575
Nat Genet. 2013 Apr;45(4):343
pubmed: 23535721
Am J Hum Genet. 2009 Oct;85(4):427-46
pubmed: 19781682
Oncogene. 2006 Sep 25;25(43):5825-31
pubmed: 16998496
Am J Hum Genet. 2010 Jul 9;87(1):139-45
pubmed: 20598278
Nature. 2007 Jun 28;447(7148):1087-93
pubmed: 17529967
PLoS Genet. 2011 Jan 13;7(1):e1001273
pubmed: 21249183
Behav Brain Res. 2001 Nov 1;125(1-2):279-84
pubmed: 11682119
Breast Cancer Res. 2011 Jan 18;13(1):R6
pubmed: 21244692
Nat Genet. 2007 Jul;39(7):870-4
pubmed: 17529973
Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361
pubmed: 27899662
Nat Genet. 2007 Jul;39(7):865-9
pubmed: 17529974
Nat Rev Genet. 2011 Jun 01;12(7):465-74
pubmed: 21629274
Nat Genet. 2007 Feb;39(2):165-7
pubmed: 17200668
BMC Res Notes. 2011 Oct 07;4:386
pubmed: 21981765
Am J Hum Genet. 2007 Sep;81(3):559-75
pubmed: 17701901
Endocr Relat Cancer. 2014 Aug;21(4):629-38
pubmed: 24919398
Trends Genet. 2012 Jul;28(7):323-32
pubmed: 22480918
Nucleic Acids Res. 2000 Jan 1;28(1):27-30
pubmed: 10592173
Nature. 2009 Oct 8;461(7265):747-53
pubmed: 19812666
Am J Hum Genet. 2010 Jun 11;86(6):929-42
pubmed: 20560208
Am J Hum Genet. 2003 May;72(5):1117-30
pubmed: 12677558
Oncogenesis. 2015 Jul 20;4:e160
pubmed: 26192618

Auteurs

Christine Lonjou (C)

Inserm, U900, Institut Curie, Paris, France.
Mines ParisTech, Fontainebleau, France.
PSL Research University, Paris, France.

Séverine Eon-Marchais (S)

Inserm, U900, Institut Curie, Paris, France.
Mines ParisTech, Fontainebleau, France.
PSL Research University, Paris, France.

Thérèse Truong (T)

Université Paris-Saclay, UVSQ, Inserm, CESP, Villejuif, France.
Inserm U1018, CESP, Team Exposome and Heredity, Villejuif, France.

Marie-Gabrielle Dondon (MG)

Inserm, U900, Institut Curie, Paris, France.
Mines ParisTech, Fontainebleau, France.
PSL Research University, Paris, France.

Mojgan Karimi (M)

Université Paris-Saclay, UVSQ, Inserm, CESP, Villejuif, France.
Inserm U1018, CESP, Team Exposome and Heredity, Villejuif, France.

Yue Jiao (Y)

Inserm, U900, Institut Curie, Paris, France.
Mines ParisTech, Fontainebleau, France.
PSL Research University, Paris, France.

Francesca Damiola (F)

Department of BioPathology, Centre Léon Bérard, Lyon, France.

Laure Barjhoux (L)

Department of BioPathology, Centre Léon Bérard, Lyon, France.

Dorothée Le Gal (D)

Inserm, U900, Institut Curie, Paris, France.
Mines ParisTech, Fontainebleau, France.
PSL Research University, Paris, France.

Juana Beauvallet (J)

Inserm, U900, Institut Curie, Paris, France.
Mines ParisTech, Fontainebleau, France.
PSL Research University, Paris, France.

Noura Mebirouk (N)

Inserm, U900, Institut Curie, Paris, France.
Mines ParisTech, Fontainebleau, France.
PSL Research University, Paris, France.

Eve Cavaciuti (E)

Inserm, U900, Institut Curie, Paris, France.
Mines ParisTech, Fontainebleau, France.
PSL Research University, Paris, France.

Jean Chiesa (J)

CHRU Hôpital Caremeau, Nîmes, France.

Anne Floquet (A)

Institut Bergonié, Bordeaux, France.

Séverine Audebert-Bellanger (S)

Département de Génétique Médicale et Biologie de la Reproduction, CHU Brest, Hôpital Morvan, Brest, France.

Sophie Giraud (S)

Service de Génétique, Hospices Civils de Lyon, Groupement Hospitalier Est, Bron, France.

Thierry Frebourg (T)

Département de Génétique, Hôpital Universitaire de Rouen, Rouen, France.

Jean-Marc Limacher (JM)

Service d'Onco-Hématologie, Hôpital Pasteur, Colmar, France.

Laurence Gladieff (L)

Service d'Oncologie Médicale, Institut Claudius Regaud-IUCT-Oncopole, Toulouse, France.

Isabelle Mortemousque (I)

Service de Génétique, Hôpital Bretonneau, Tours, France.

Hélène Dreyfus (H)

Clinique Sainte Catherine, Avignon, France.
Département de Génétique, CHU de Grenoble, Hôpital Couple-Enfant, Grenoble, France.

Sophie Lejeune-Dumoulin (S)

Service de Génétique Clinique Guy Fontaine, CHU Lille, Lille, France.

Christine Lasset (C)

Université Claude Bernard Lyon 1, Villeurbanne, France.
CNRS UMR 5558, Lyon, France.
Centre Léon Bérard, Unité de Prévention et Epidémiologie Génétique, Lyon, France.

Laurence Venat-Bouvet (L)

Service d'Oncologie Médicale, Hôpital Universitaire Dupuytren, Limoges, France.

Yves-Jean Bignon (YJ)

Département d'Oncogénétique, Université Clermont Auvergne, UMR INSERM, U1240, Centre Jean Perrin, Clermont Ferrand, France.

Pascal Pujol (P)

Hôpital Arnaud de Villeneuve, CHU Montpellier, Service de Génétique Médicale et Oncogénétique, Montpellier, France.
INSERM 896, CRCM Val d'Aurelle, Montpellier, France.

Christine M Maugard (CM)

Département d'Oncobiologie, LBBM, Hôpitaux Universitaires de Strasbourg, Génétique Oncologique Moléculaire, UF1422, Strasbourg, France.
Hôpitaux Universitaires de Strasbourg, UF6948 Génétique Oncologique Clinique, Évaluation Familiale et Suivi, Strasbourg, France.

Elisabeth Luporsi (E)

ICL Alexis Vautrin, Unité d'Oncogénétique, Vandœuvre-lès-Nancy, France.

Valérie Bonadona (V)

Université Claude Bernard Lyon 1, Villeurbanne, France.
CNRS UMR 5558, Lyon, France.
Centre Léon Bérard, Unité de Prévention et Epidémiologie Génétique, Lyon, France.

Catherine Noguès (C)

Département d'Anticipation et de Suivi des Cancers, Oncogénétique Clinique, Institut Paoli-Calmettes, Marseille, France.
Aix Marseille University, INSERM, IRD, SESSTIM, Marseille, France.

Pascaline Berthet (P)

Département de Biopathologie, Centre François Baclesse, Oncogénétique, Caen, France.

Capucine Delnatte (C)

Institut de Cancérologie de l'Ouest, Unité d'Oncogénétique, Saint Herblain, France.

Paul Gesta (P)

CH Georges Renon, Service d'Oncogénétique Régional Poitou-Charentes, Niort, France.

Alain Lortholary (A)

Centre Catherine de Sienne, Service d'Oncologie Médicale, Nantes, France.

Laurence Faivre (L)

Institut GIMI, CHU de Dijon, Hôpital d'Enfants, Dijon, France.
Oncogénétique, Centre de Lutte contre le Cancer Georges François Leclerc, Dijon, France.

Bruno Buecher (B)

Institut Curie, Service de Génétique, Paris, France.

Olivier Caron (O)

Département de Médecine Oncologique, Gustave Roussy, Villejuif, France.

Marion Gauthier-Villars (M)

Institut Curie, Service de Génétique, Paris, France.

Isabelle Coupier (I)

Hôpital Arnaud de Villeneuve, CHU Montpellier, Service de Génétique Médicale et Oncogénétique, Montpellier, France.
INSERM 896, CRCM Val d'Aurelle, Montpellier, France.

Sylvie Mazoyer (S)

Equipe GENDEV, Centre de Recherche en Neurosciences de Lyon, Inserm U1028, CNRS UMR5292, Université Lyon 1, Université St Etienne, Lyon, France.

Luis-Cristobal Monraz (LC)

Inserm, U900, Institut Curie, Paris, France.
Mines ParisTech, Fontainebleau, France.
PSL Research University, Paris, France.

Maria Kondratova (M)

Inserm, U900, Institut Curie, Paris, France.
Mines ParisTech, Fontainebleau, France.
PSL Research University, Paris, France.

Inna Kuperstein (I)

Inserm, U900, Institut Curie, Paris, France.
Mines ParisTech, Fontainebleau, France.
PSL Research University, Paris, France.

Pascal Guénel (P)

Université Paris-Saclay, UVSQ, Inserm, CESP, Villejuif, France.
Inserm U1018, CESP, Team Exposome and Heredity, Villejuif, France.

Emmanuel Barillot (E)

Inserm, U900, Institut Curie, Paris, France.
Mines ParisTech, Fontainebleau, France.
PSL Research University, Paris, France.

Dominique Stoppa-Lyonnet (D)

Institut Curie, Service de Génétique, Paris, France.
Inserm, U830, Université Paris-Descartes, Paris, France.

Nadine Andrieu (N)

Inserm, U900, Institut Curie, Paris, France.
Mines ParisTech, Fontainebleau, France.
PSL Research University, Paris, France.

Fabienne Lesueur (F)

Inserm, U900, Institut Curie, Paris, France.
Mines ParisTech, Fontainebleau, France.
PSL Research University, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH